Search results
22 gru 2021 · Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized patients...
- Correspondence Mar 17, 2022 Outpatient Remdesivir to Prevent Progression to Severe Covid-19
Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to...
- Free Full Text
Remdesivir (GS-5734), an inhibitor of the viral...
- Editorial Jan 27, 2022 The Goldilocks Time for Remdesivir — Is Any Indication Just Right E.L. Heil and S. Kottilil
Gottlieb et al. conducted a clinical trial — the results of...
- Original Article Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma H. Tilly and Others
Diffuse large B-cell lymphoma (DLBCL) is typically treated...
- Original Article Cardiovascular and Cancer Risk With Tofacitinib in Rheumatoid Arthritis S.R. Ytterberg and Others
Patients received tofacitinib at a dose of 5 mg or 10 mg...
- Interactive Medical Case Up in The Air J.V. Loewenthal and Others
This interactive case features a 58-year-old man who reports...
- Editorial The Price of Freedom From Tricuspid Regurgitation J. Chikwe and M. Gaudino
From the Department of Cardiac Surgery, Smidt Heart...
- Perspective Please Don't Keep Me A. Drutchas
Early Remdesivir to Prevent Progression to Severe Covid-19...
- Correspondence Mar 17, 2022 Outpatient Remdesivir to Prevent Progression to Severe Covid-19
Treatment with remdesivir for three days in ambulatory patients reduced hospitalizations and COVID-19-related medically attended visits throughout day 28 (HR: 0.28; 95% CI: 0.1, 0.75, low CoE; and HR: 0.19; 95% CI: 0.07, 0.56, low CoE, respectively).
22 maj 2020 · Remdesivir (GS-5734), an inhibitor of the viral RNA-dependent, RNA polymerase with in vitro inhibitory activity against SARS-CoV-1 and the Middle East respiratory syndrome (MERS-CoV), 5-8 was...
22 kwi 2022 · Pfizer’s oral antiviral drug (a combination of nirmatrelvir and ritonavir tablets) is strongly recommended for patients with non-severe COVID-19 who are at highest risk of developing severe disease and hospitalization, such as unvaccinated, older, or immunosuppressed patients.
27 maj 2020 · Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19). Methods.
20 paź 2020 · Scientists randomly assigned 1,062 hospitalized COVID-19 patients to receive remdesivir or a placebo plus standard treatment. The patients received an intravenous infusion of remdesivir or placebo for up to 10 days.
30 lip 2020 · Current practice Remdesivir has received worldwide attention as a potentially effective treatment for severe covid-19. After rapid market approval in the US, remdesivir is already being used in clinical practice.
